BiotechTube
Arctoris

Arctoris

Oxford, United Kingdom· Est.
arctoris.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.8M

Overview

Arctoris, founded in 2016 and spun out of the University of Oxford, addresses the critical bottleneck of data quality and reproducibility in drug discovery. The company operates as a Partnership Research Organisation (PRO), offering automated experimental services powered by its proprietary Ulysses® robotic platform to generate industrial-scale, FAIR-compliant datasets. By integrating deep biological expertise with automation and data science, Arctoris enables its partners to accelerate R&D with high-quality, AI-ready data, positioning itself at the intersection of techbio and traditional CRO services.

Drug DeliveryAI / Machine Learning

Technology Platform

Ulysses®: A fully robotic, cloud-controlled discovery platform that automates entire assay cascades across biochemistry, biophysics, cell biology, and structural biology. It generates precise, reproducible, and FAIR-compliant datasets in real-time for AI/ML readiness.

Funding History

4
Total raised:$10.8M
Seed$2.8M
Series A$5M
Seed$1.5M
Seed$1.5M

Opportunities

The growing reliance on AI/ML in drug discovery creates a massive demand for the high-quality, structured, and reproducible data that Arctoris's Ulysses platform is designed to produce.
The company is also well-positioned to serve the capital-efficient virtual biotech and techbio sector, which lacks wet-lab infrastructure but needs robust experimental validation.

Risk Factors

Key risks include the high capital and maintenance costs of a robotic platform, the challenge of convincing traditional biopharma to adopt a new service model, and competition from large CROs investing in automation and other techbio startups.
Dependency on venture funding prior to profitability is also a financial risk.

Competitive Landscape

Arctoris competes with traditional contract research organizations (CROs) that are adding automation, as well as with other techbio companies offering data-centric discovery services. Its differentiation lies in its fully integrated, platform-first approach (Ulysses), its focus on data quality for AI, and its Partnership Research Organisation (PRO) model of deep collaboration.

More companies in AI / Machine Learning →More companies in United Kingdom →